AIBD Conference

Recognizing and Managing Iron Deficiency Anemia in Inflammatory Bowel Disease

Program Information

Target Audience

This activity has been designed to meet the educational needs of gastroenterologists and other healthcare providers involved in the care of patients with iron deficiency anemia (IDA) in Inflammatory Bowel Disease (IBD).

Educational Objectives

After completing this program, participants should be better able to:

Describe the prevalence of IDA in patients with IBD

Proactively identify patients with IDA

Describe the pathophysiologic processes that underlie IDA in patients with IBD

Differentiate among various oral and IV iron formulations and incorporate them effectively into clinical practice


Continuing Education

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Imedex and Purdue University. Purdue University is accredited by the ACCME to provide continuing medical education for physicians.

In support of improving patient care, this activity has been planned and implemented by North American Center for Continuing Medical Education (NACCME), Imedex, and Purdue University. NACCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Statements


Physicians

Purdue University designates this live educational activity for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Nursing

This continuing nursing education activity awards 1.25 contact hours. This activity will also award pharmacotherapeutic contact hours; however, the final assignment of these contact hours will be announced once all content has been approved.

Provider approved by the California Board of Registered Nursing, Provider #13255 for 1.25 contact hours.

Pharmacy

This live, knowledge-based activity (Universal Activity Number: JA0006201-9999-18-232-L01-P has been approved for a maximum of 1.25 contact hours (0.125 CEUs). The certificate is not the official record of your participation in the activity. The official record of credit will be the information in CPE Monitor system. The deadline to claim credit is February 13, 2019 (60 days from the end of the activity). Following ACPE Policy, NACCME will not be able to report your claimed credit to CPE Monitor after this 60-day period. Eligibility for pharmacy credit is contingent upon the successful completion of a post-test and/or evaluation for each activity or session attended.

Requirements for Credit

To be eligible for documentation of credit for each session attended, participants must participate in the activity and complete the online general survey and the online evaluation. Once surveys are completed, participants may immediately print their documentation of credit.

For questions regarding this activity, please email OfficeOfCME@imedex.com.

ADA Statement

Imedex / North American Center for Continuing Medical Education complies with the legal requirements of the Americans with Disabilities Act and the rules and regulations thereof. If any participant in this educational activity is in need of accommodations, please call (770) 751-7332 / (609) 371-1137.

Privacy Policy

Imedex / NACCME protects the privacy of personal and other information regarding participants, educational partners, and joint sponsors. Imedex, NACCME and our joint providers will not release personally identifiable information to a third party without the individual’s consent, except such information as is required for reporting purposes to the appropriate accrediting agency.

NACCME maintains physical, electronic, and procedural safeguards that comply with federal regulations to guard your nonpublic personal information.

Disclosure of Relevant Financial Relationships

As an accredited provider of continuing medical education, Purdue University, NACCME, LLC, and Imedex, LLC require anyone in a position to affect the activity's subject matter to disclose any financial relationships they have as related to the contents of their presentations. The existence of commercial or financial interests of presenters related to the subject matter of their presentations should not be construed as implying bias or decreasing the value of their presentations. However, disclosure should help participants form their own judgments.

All presenters were independently selected by the organizing committee. Those presenters who disclosed affiliations or financial interests with the commercial organizations involved with products, to which they may refer, are listed below.

Stephen B. Hanauer, MD, FACG has received clinical research support from AbbVie Inc., Allergan, Amgen Inc., Celgene Corporation, Genentech, GlaxoSmithKline, Janssen Products, LP, Eli Lilly and Company, Novartis, Pfizer Inc., Prometheus Laboratories Inc., Receptos, Inc., Sanofi-Avantis, Takeda Pharmaceuticals U.S.A., Inc. and UCB, Inc. Dr. Hanauer is a consultant for AbbVie Inc., Actavis, Allergan, Amgen Inc., Arena, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene Corporation, Celltrion Inc., Ferring Pharmaceuticals Inc., Genentech, GlaxoSmithKline, Hospira, Inc., Janssen Products, Eli Lilly and Company, Merck, Nestle, Novartis, Pfizer Inc., Prometheus Laboratories Inc., Receptos, Inc., Salix Pharmaceuticals, Inc., Samsung Bioepis, Sanofi-Avantis, Seres Health, Shire, Takeda Pharmaceuticals U.S.A., Inc., Therakos, Tigenex, UCB, Inc. and VHsquared. Dr. Hanauer is on the data and safety monitoring board for Bristol-Myers Squibb. Dr. Hanauer is a speaker for AbbVie Inc., Janssen Products, LP and Takeda Pharmaceuticals U.S.A., Inc.

Gary R. Lichtenstein, MD is an author for McMahon Publishing and UpToDate, Inc. Dr. Lichtenstein has book royalty for SLACK Incorporated. Dr. Lichtenstein is an editor for Clinical Advances in Gastroenterology, Gastroenterology and Hepatology (Gastro-Hep Communications), and Springer Science and Business Media. Dr. Lichtenstein is a consultant for Abbott/AbbVie, Actavis, Alaven Pharmaceutical LLC, Celgene, Ferring Pharmaceuticals Inc., Hospira, Inc., Janssen Orthobiotech (Funding to University of PA IBD Fellow Education), Luitpold Pharmaceuticals, Inc./American Regent, Inc., Pfizer Inc. (Funding to the University of PA IBD Fellow Education), Prometheus Laboratories Inc., Romark, L.C., Salix Pharmaceuticals, Inc., Santarus, Inc., Shire Pharmaceuticals, Receptos, Takeda (Funding to University of PA IBD Fellow Education), and UCB, Inc. Dr. Lichtenstein has received honoraria from Clinical Advances in Gastroenterology, Therapeutic Advances in Gastroenterology, Gastroenterology & Hepatology (Gastro-Hep Communications), Ironwood Pharmaceuticals, Inc., Luitpold Pharmaceuticals, Inc./American Regent, Inc. (CME Programs), Merck (CME Programs), McMahonPublishing, Springer Science and Business Media, UpToDate, and Romark (CME Programs). Dr. Lichtenstein has received grant/research support from Celgene, Janssen Orthobiotech (Funding to University of PA IBD Fellow Education), Salix Pharmaceuticals, Inc., Santarus, Inc., Shire Pharmaceuticals, Receptos and UCB, Inc.

Edward V. Loftus, Jr., MD has received grant/research support from AbbVie, Amgen, Celgene, Genentech, Gilead, Janssen, MedImmune, Pfizer, Robarts Clinical Trials, Seres, Takeda and UCB. Dr. Loftus is a consultant for AbbVie, Amgen, Allergan, Bristol-Myers Squibb, Celltrion, Eli Lilly, Janssen, Pfizer, Takeda and UCB. Dr. Loftus is on the speaker's bureau for AbbVie, Amgen, Allergan, Bristol-Myers Squibb, Celltrion, Eli Lilly, Janssen, Pfizer, Takeda and UCB.

NACCME, LLC & Imedex, LLC Staff Disclosure of Financial Relationships

All Imedex staff members who are in a position to control content of this activity have no financial relationships with any commercial interests, except for the following individuals:

Chris Bolwell owns shares of stock of GlaxoSmithKline.

NACCME, LLC and Imedex, LLC are independent providers of continuing medical education. Neither NACCME nor Imedex, LLC. have no proprietary or financial interest in medical or healthcare products over which the FDA (USA) or EMA (EU) has regulatory authority.

Purdue University Staff Disclosure of Financial Relationships

All Purdue planners, reviewers and staff have no financial relationships to disclose.

Focus Medical Staff Disclosure of Financial Relationships

All Focus Medical staff have no financial relationships to disclose.

Unapproved and Investigational Uses of Drugs and Devices

This activity may contain information about experimental and other uses of drugs or devices that are not currently approved by the European Medicines Agency (EMA) of the European Union or the Food and Drug Administration (FDA) of the United States. Participants are strongly encouraged to consult approved product labeling for any drug or device mentioned in this activity before use. The opinions expressed during this activity are the opinions of the respective authors, presenters or moderators and do not necessarily reflect the opinions of Imedex.

Disclaimer

The material presented and related discussions are not intended to be medical advice, and the presentation or discussion of such material is not intended to create and does not establish a physician-patient relationship. Medical advice of any nature should be sought from an individual’s own physician.

Neither Imedex, NACCME, nor any of its subsidiaries or affiliates is affiliated with or formally endorsed by a medical society.

About Imedex

Imedex is a brand and assumed name used by Imedex, LLC (hereby referred to as Imedex). Imedex is solely responsible for this agenda’s content. Although Imedex attempts to ensure that the information in our program is accurate and timely, matters and opinions discussed and/or presented with respect to clinical matters are those of the discussion participants only, and not necessarily those of Imedex. Moreover, although Imedex attempts to identify and integrate the most qualified medical professionals in our program, TO THE FULLEST EXTENT PERMITTED BY LAW, IMEDEX EXPRESSLY DISCLAIM ALL WARRANTIES, EITHER EXPRESS OR IMPLIED, STATUTORY OR OTHERWISE, INCLUDING BUT NOT LIMITED TO THE IMPLIED WARRANTIES OF MERCHANTABILITY, NON-INFRINGEMENT OF THIRD PARTIES’ RIGHTS, AND FITNESS FOR A PARTICULAR PURPOSE, WITH RESPECT TO THE CONTENT PRESENTED. IMEDEX FURTHER MAKES NO REPRESENTATIONS OR WARRANTIES ABOUT THE ACCURACY, RELIABILITY, COMPLETENESS OR TIMELINESS OF THE CONTENT OR ANY MATERIAL PRESENTED.

Copyright © 2018 by Imedex, LLC, and North American Center for Continuing Medical Education, LLC. All rights reserved. No part of this accredited continuing education activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from Imedex or North American Center for Continuing Medical Education.

Accredited by

Provided by Gi Health Foundation

A satellite symposium held in conjunction with the 2018 Advances in Inflammatory Bowel Diseases Conference: Multidisciplinary Approaches to IBD Patient-Centered Care.
Supported by an educational grant from American Regent, Inc.

For more information, email us at info@GiHealthFoundation.org, or call 1-877-782-4532.

JOIN THE DISCUSSION AT OUR INTERACTIVE
CME BREAKFAST SYMPOSIUM!

  • SELECT A SPEAKER
    TO VIEW THEIR BIO

    Stephen B. Hanauer, MD, FACG

    (CHAIR)
    Chicago, IL

  • Edward V. Loftus, Jr., MD

    Rochester, MN

  • Gary R. Lichtenstein, MD

    Philadelphia, PA

FRIDAY,
DECEMBER 14, 2018

Registration/Breakfast: 6:00 AM
CME Symposium: 6:15 - 7:30 AM

On-site registration is available.
Space is limited; please arrive by 6:00 AM.

WALT DISNEY WORLD
DOLPHIN HOTEL

1500 Epcot Resorts Boulevard
Northern Hemisphere C-D (Level 5)
Lake Buena Vista, FL 32830

Agenda

6:00 AM

Registration/Seating/Buffet

6:15 AM

Introduction & Preliminary Cases

6:25 AM

Understanding Iron Deficiency Anemia in Gastroenterology -
Who and Why?

6:35 PM

Anemia Diagnosis for the Gastroenterologist -
Signs, Symptoms and Diagnosis

6:45 AM

Iron Replacement Therapy -
What Are My Options?

7:10 AM

Case Studies in Iron Deficiency Anemia

7:20 AM

Panel Discussion/Q&A

7:30 AM

Closing Remarks

Stephen B. Hanauer, MD, FACG
(Chair)
Northwestern University Feinberg School of Medicine
Clifford Joseph Barborka Professor of Medicine
Medical Director, Digestive Diseases Center
Chicago, Illinois

Stephen B. Hanauer, MD, is a past president of the American College of Gastroenterology. He completed his medical degree, with honors, at the University of Illinois in Chicago. His postdoctoral training included an internship and residency in internal medicine, as well as a fellowship in gastroenterology at the University of Chicago. He rose through the academic ranks at the University of Chicago to become professor of medicine, and was subsequently awarded the Joseph B. Kirsner Chair in Medicine and became the designated chief of the Gastroenterology, Hepatology, and Nutrition section, where he served from 2000 to 2013. He was recruited as medical director for the Digestive Health Center at Northwestern Medicine, and became the Clifford Joseph Barborka Professor of Medicine at Northwestern’s Feinberg School of Medicine in 2014.

Dr. Hanauer is board certified in internal medicine and gastroenterology by the American Board of Internal Medicine and by the American Board of Gastroenterology, respectively. He holds memberships in several professional societies and is a fellow of the American Gastroenterological Association (AGA), the American College of Gastroenterology, and the American College of Physicians. In connection with the AGA, Dr. Hanauer served as chair of the Inflammation, Immunology, and Inflammatory Bowel Disease section and the Clinical Practice section, and subsequently served as councilor for clinical research on the AGA Governing Board. He is a prior member of the Specialty Board of the American Board of Internal Medicine. Among his many honors, Dr. Hanauer received the AGA/Miles and Shirley Fiterman Foundation, Joseph B. Kirsner Award in Gastroenterology in 2001 and the Janssen Award for Clinical Excellence in 2004. He has served as a member and chair of the US Food and Drug Administration Advisory Panel for Gastrointestinal Disorders, and is a member and former chairman of the International Organization for Inflammatory Bowel Disease.

Dr. Hanauer has authored hundreds of peer-reviewed journal articles, books and book chapters, abstracts, monographs, and editorials. He is the former editor in chief of Nature Clinical Practice Gastroenterology & Hepatology and currently serves as associate editor (IBD) of Clinical Gastroenterology and Hepatology. He is also a member of the editorial boards of numerous journals, including the American Journal of Gastroenterology and Inflammatory Bowel Diseases.

A special congratulations to Dr Hanauer as he was selected as the College's 2018 Berk/Fise Clinical Achievement Award winner.

SPEAKER DISCLOSURES

Clinical Research:  AbbVie Inc., Allergan, Amgen Inc., Celgene Corporation, Genentech, GlaxoSmithKline, Janssen Products, LP, Eli Lilly and Company, Novartis, Pfizer Inc., Prometheus Laboratories Inc., Receptos, Inc., Sanofi-Avantis, Takeda Pharmaceuticals U.S.A., Inc., UCB, Inc.

Consultant:  AbbVie Inc., Actavis, Allergan, Amgen Inc., Arena, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene Corporation, Celltrion Inc., Ferring Pharmaceuticals Inc., Genentech, GlaxoSmithKline, Hospira, Inc., Janssen Products, Eli Lilly and Company, Merck, Nestle, Novartis, Pfizer Inc., Prometheus Laboratories Inc., Receptos, Inc., Salix Pharmaceuticals, Inc., Samsung Bioepis, Sanofi-Avantis, Seres Health, Shire, Takeda Pharmaceuticals U.S.A., Inc., Therakos, Tigenex, UCB, Inc., VHsquared

Data and Safety Monitoring Board:  Bristol-Myers Squibb Company

Speaker:  AbbVie Inc., Janssen Products, LP, Takeda Pharmaceuticals U.S.A., Inc.

Edward V. Loftus, Jr., MD
Professor of Medicine
Director, Inflammatory Bowel Disease Interest Group
Division of Gastroenterology and Hepatology
Mayo Clinic
Rochester, Minnesota

Edward V. Loftus, Jr. earned a medical degree at the University of Pennsylvania and completed a residency in internal medicine at Temple University Health Sciences Center in Philadelphia. He served one year as a general medical officer in the Indian Health Service at Fort Belknap P.H.S. Indian Hospital in Harlem, Montana, and then completed a fellowship in gastroenterology at the Mayo Graduate School of Medicine. He has been on the Mayo Clinic consulting staff since 1995.

Dr. Loftus is a Fellow of the American College of Physicians (ACP), the American College of Gastroenterology (ACG), and the American Gastroenterological Association (AGA). He is a member of several professional societies, including the ACP, AGA, ACG, American Society for Gastrointestinal Endoscopy, and the Crohn’s & Colitis Foundation of America (CCFA). He served as Chair of the Patient Education Committee of the CCFA from 2002 to 2005. He has served on several ACG committees, and has been an abstract reviewer for both AGA and ACG for a number of years. He was the Vice-Chair and then the Chair of the Immunology, Microbiology, and Inflammatory Bowel Disease section of the AGA Institute Council between 2012 and 2016.

Among Dr. Loftus’s awards are the Mayo Department of Medicine Laureate Award (2007) and the CCFA, Minnesota - Dakotas Chapter, Physician of the Year Award (2008). He was elected to membership in the International Organization for the Study of Inflammatory Bowel Disease (IOIBD) in 2008. Dr Loftus was named Teacher of the Year by the Mayo gastroenterology fellows in 2010-11 and has been named honorable mention several years. He has been named to the list of Best Doctors in America since 2005 and to Castle Connolly’s Top Doctors in America list since 2010.

He served as Associate Editor of the American Journal of Gastroenterology between 2003 and 2009, and as Associate Editor of Inflammatory Bowel Diseases from 2006 to 2013.

Dr. Loftus has published over 350 original articles, book chapters, or editorials and more than 500 abstracts, and has lectured extensively on the epidemiology, natural history, diagnosis, and medical management of inflammatory bowel diseases. Dr. Loftus has served as the principal investigator on several funded studies focusing on the epidemiology and natural history of inflammatory bowel disease, and has served as the local PI on multiple clinical trials of investigational agents for IBD.

SPEAKER DISCLOSURES

Grants/Research Support:  AbbVie, Amgen, Celgene, Genentech, Gilead, Janssen, MedImmune, Pfizer, Robarts Clinical Trials, Seres, Takeda, UCB

Consultant/Speaker Bureau:  AbbVie, Amgen, Allergan, Bristol-Myers Squibb, Celltrion, Eli Lilly, Janssen, Pfizer, Takeda, UCB

Gary R. Lichtenstein, MD
Professor of Medicine
Raymond and Ruth Perelman School of Medicine
Director, Center for Inflammatory Bowel Disease
Department of Medicine
Division of Gastroenterology
University of Pennsylvania
Philadelphia, Pennsylvania

Gary R. Lichtenstein, MD, FACP, FACG, AGAF, is the director of the Inflammatory Bowel Disease Program in the Department of Medicine’s Division of Gastroenterology at the Hospital of the University of Pennsylvania, and a professor of medicine at the University of Pennsylvania’s Perelman School of Medicine in Philadelphia, Pennsylvania.

Dr. Lichtenstein earned his medical degree from the Mount Sinai School of Medicine, in New York, New York. He then completed his internship and residency in internal medicine at Duke University Medical Center in Durham, North Carolina. He also completed a fellowship in gastroenterology at the Hospital of the University of Pennsylvania in the University of Pennsylvania School of Medicine. His current research interests encompass investigational therapies for the treatment of ulcerative colitis and Crohn’s disease, and he has received numerous research grants focusing on these areas. Dr. Lichtenstein has served as the national/international principal investigator evaluating novel agents for therapeutic trials in the treatment of ulcerative colitis and Crohn's disease.

A fellow of the American Gastroenterological Association (AGA), the American College of Physicians, and the American College of Gastroenterology (ACG), Dr. Lichtenstein has been listed in Best Doctors in America (inflammatory bowel disease), and has served as medical secretary for the gastroenterology section of the American Board of Internal Medicine. He holds membership and committee positions in many professional societies at a national level, including the AGA, where he has served as chair of the Clinical Practice Updates Committee and as vice chair of the Clinical Practice Updates Committee and the Practice Management Economics Committee; the American Society for Gastrointestinal Endoscopy, where he has served on the Committee on Training; and the ACG, where he has served on the Educational Affairs Committee, the programs committee, and the nominations committee, as well as recently serving as a member of the Research Committee.

Dr. Lichtenstein has also been the chair of the abstract review committee for inflammatory bowel disease for the ACG. He is a member of the Crohn’s & Colitis Foundation of America (CCFA), where he served at the national level as the chair of the Membership Committee of the Clinical Research Alliance, on the national grants review committee, and on the national physician education committee. In addition, he is a longstanding member of the American College of Physicians and the American Medical Association. Dr. Lichtenstein has received numerous awards in the University of Pennsylvania Health System, including the Louis Duhring Outstanding Clinical Specialist Award, the Lindback Award for Distinguished Teaching (the top teaching award at the University of Pennsylvania), and the Penn Pearls Award, the medical school teaching award. He has received the Department of Medicine Housestaff teaching award, the Donald B. Martin Teaching Service Award, and the Gastroenterology Division Sidney Cohen Teaching Award for Faculty. He is listed in The Best Doctors in America (inflammatory bowel disease) and in Philadelphia Magazine as being among the top gastroenterologists for the elderly in Philadelphia and among the top gastroenterologists in Philadelphia (special focus: inflammatory bowel disease). He is also the recipient of the CCFA Physician of the Year Award (Philadelphia/Delaware Valley Chapter). In addition to having served on the editorial board of the journals Gastroenterology, the American Journal of Gastroenterology, Inflammatory Bowel Diseases, the World Journal of Gastroenterology, and Digestive Diseases and Sciences, Dr. Lichtenstein has served as a former writer of selected summaries in the journal Gastroenterology, as the section editor of selected summaries, and as the section editor of print and media reviews in gastroenterology for a five-year term. He has also served and currently serves as a reviewer for such journals as the New England Journal of Medicine, Gastroenterology, The Lancet, the Annals of Internal Medicine, Gut, the Journal of Parenteral and Enteral Nutrition, the American Journal of Gastroenterology, the World Journal of Gastroenterology, and the Journal of Clinical Gastroenterology. He is executive editor of the newly PubMed-indexed journal Gastroenterology & Hepatology, and serves as associate editor of Therapeutic Advances in Gastroenterology, The Physician and Sportsmedicine, and the Journal of Clinical Investigation. He is currently assistant editor in chief of the World Journal of Gastroenterology. An invited lecturer at the local, national, and international level, Dr. Lichtenstein is the author or coauthor of more than 250 peer-reviewed primary articles, chapters, letters, and editorials. He has presented over 250 abstracts and edited 18 books. He has lectured at a national and international level at more than 300 invited conferences, symposia, and institutional grand rounds.

SPEAKER DISCLOSURES

Author:  McMahonPublishing, and UpToDate, Inc.

Book Royalty:  SLACK Incorporated Editor: Clinical Advances in Gastroenterology, Gastroenterology and Hepatoloty (Gastro-Hep Communications), and Springer Science and Business Media

Consultant:  Abbott/AbbVie Inc., Actavis, Alaven Pharmaceutical LLC, Celgene, Ferring Pharmaceuticals Inc., Hospira, Inc., Janssen Orthobiotech (Funding to University of PA IBD Fellow Education), Luitpold Pharmaceuticals, Inc./American Regent, Inc., Pfizer Inc. (Funding to the University of PA IBD Fellow Education), Prometheus Laboratories Inc., Romark, L.C., Salix Pharmaceuticals, Inc./Valeant, Santarus, Inc., Shire Pharmaceuticals, Receptos, Takeda (Funding to University of PA IBD Fellow Education), and UCB, Inc.

Honoraria: Clinical Advances in Gastroenterology, Therapeutic Advances in Gastroenterology, Gastroenterology & Hepatology (Gastro-Hep Communications), Ironwood Pharmaceuticals, Inc., Luitpold Pharmaceuticals, Inc./American Regent, Inc. (CME Programs), Merck (CME Programs), McMahonPublishing, Springer Science and Business Media, UpToDate, and Romark (CME Programs)

Research: Celgene, Janssen Orthobiotech (Funding to University of PA IBD Fellow Education), Salix Pharmaceuticals, Inc./Valeant, Santarus, Inc., Shire Pharmaceuticals, and Receptos, UCB, Inc.

© Copyright 2013-2018 GI Health Foundation. All rights reserved.
This site is maintained as an educational resource for US healthcare providers only. Use of this website is governed by the GIHF terms of use and privacy statement.